meta_pixel
Tapesearch Logo
Log in
Plenary Session

5.36 - ASH UPDATE #4 - GEM CESAR

Plenary Session

Vinay Prasad, MD MPH

Health, Medicine, Policy, Oncology, Science & Medicine

4.7789 Ratings

🗓️ 30 December 2022

⏱️ 22 minutes

🧾️ Download transcript

Summary

I break down the GEM CESAR trial K, R, D, Pom, Dara, Dex, R, and Auto and all before you actually have cancer What a crazy trial!

Transcript

Click on a timestamp to play from that location

0:00.0

Welcome back to Ash Updates. This is abstract number four, Jim Caesar. It's entitled to Curative Strategy for

0:07.6

High-Riss smoldering myeloma, post hoc analysis, a sustained undetectable mineral residual disease.

0:13.5

This is by Marie Matales and colleagues from the Spanish group. No group has been more responsible

0:18.9

for useless studies in smoldering myeloma.

0:23.2

And the Spanish group, they're at it again with the Jim Caesar study.

0:26.8

I've not seen anything like this.

0:28.2

This really boggles the mind if you think about it.

0:31.3

And by the end of this video, I'm going to make a plea that IRBs put an end to this.

0:41.1

We need to stop uncontrolled studies with the kitchen sink for smoldering myeloma. All right, let's see what's going on in Jim Caesar. Disclosures.

0:46.3

Oh my God. They don't have a disclosure slide in the video. I didn't see one. I didn't even see

0:51.3

one at the top of the session, but I noticed that the authors have

0:54.6

many, many disclosure, Honoraria, Pfizer, Sanofi, Takeda, Oncapeptides. Aren't they the makers of

1:00.7

that useless product milflufen that's been withdrawn from market? Bristol-Myers Squibb, Seljean,

1:06.1

Jansen. I guess if you have conflicts with everyone of the companies, they all cancel each other

1:10.5

out.

1:10.9

It's a vector of canceling out, I suppose.

1:13.8

This is not good.

1:15.1

It's not good to take money from all of the companies in the space.

1:18.1

And then, advance market share with uncontrolled studies that are done in smoldering myeloma

1:23.8

where you use up all these drugs, okay?

1:26.1

This makes it seem like your primary goal is to enrich the companies and not actually to improve

1:31.7

outcomes for patients.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2025.